System and method for cell levitation and monitoring
US-2024361343-A1 · Oct 31, 2024 · US
Controlling Pseudomonas aeruginosa persister cells with GM-CSF
US9370189B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9370189-B2 |
| Application number | US-201313897842-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2013 |
| Priority date | May 18, 2012 |
| Publication date | Jun 21, 2016 |
| Grant date | Jun 21, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to host immune factors and antibiotics and, more particularly, to a system and method for controlling and reducing the antibiotic tolerance of bacterial persister cells with host immune factors.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reducing the number of viable bacterial persister cells in a population of persister cells, comprising the steps of: providing a population of cells comprising a sub-population of normal cells and a sub-population of persister Pseudomonas aeruginosa cells; isolating the sub-population of persister cells from the sub-population of normal cells, by contacting the population with an antibiotic, wherein the antibiotic is ciprofloxacin; contacting at least one persister cell in the sub-population of persister cells, with a human immune factor, wherein said human immune factor is GM-CSF, and with a predetermined amount of at least one antibiotic wherein said at least one antibiotic is selected from the group consisting of tobramycin, ciprofloxacin, and tetracycline, wherein the step of contacting results in reduction of viable persister cells in the sub-population of persister cells. 2. The method of claim 1 , wherein the GM-CSF is made by one or multiple domains of GM-CSF. 3. The method of claim 1 , further comprising the step of contacting at least one persister cell in the population of persister cells with a predetermined amount of alginate lyase.
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Poly(beta-D-mannuronate) lyase (4.2.2.3) · CPC title
having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins · CPC title
Assays involving cytokines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9370189B2 cover?
- The present invention relates to host immune factors and antibiotics and, more particularly, to a system and method for controlling and reducing the antibiotic tolerance of bacterial persister cells with host immune factors.
- Who is the assignee on this patent?
- Ren Dacheng, Choudhary Geetika S, Yao Xiangyu, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).